# Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy

> **NCT04161053** · PHASE3 · RECRUITING · sponsor: **Tanta University** · enrollment: 60 (estimated)

## Conditions studied

- Hepatic Encephalopathy

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Nitazoxanide

## Key facts

- **NCT ID:** NCT04161053
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-11-01
- **Primary completion:** 2028-11
- **Final completion:** 2028-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04161053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04161053, "Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04161053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*